KR101905050B1 - 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법 - Google Patents

암 또는 전암성 질환을 치료하기 위한 인터레이스 방법 Download PDF

Info

Publication number
KR101905050B1
KR101905050B1 KR1020177022797A KR20177022797A KR101905050B1 KR 101905050 B1 KR101905050 B1 KR 101905050B1 KR 1020177022797 A KR1020177022797 A KR 1020177022797A KR 20177022797 A KR20177022797 A KR 20177022797A KR 101905050 B1 KR101905050 B1 KR 101905050B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
cancer
administration
cell
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177022797A
Other languages
English (en)
Korean (ko)
Other versions
KR20170097237A (ko
Inventor
앤드류 제이. 크라우스
로이드 에스. 그레이
티모시 맥도널드
조엘 린든
Original Assignee
타우 쎄라퓨틱스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타우 쎄라퓨틱스 엘엘씨 filed Critical 타우 쎄라퓨틱스 엘엘씨
Publication of KR20170097237A publication Critical patent/KR20170097237A/ko
Application granted granted Critical
Publication of KR101905050B1 publication Critical patent/KR101905050B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020177022797A 2009-06-05 2010-06-04 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법 Expired - Fee Related KR101905050B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18465809P 2009-06-05 2009-06-05
US61/184,658 2009-06-05
PCT/US2010/037437 WO2010141842A2 (en) 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117031182A Division KR20120030112A (ko) 2009-06-05 2010-06-04 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법

Publications (2)

Publication Number Publication Date
KR20170097237A KR20170097237A (ko) 2017-08-25
KR101905050B1 true KR101905050B1 (ko) 2018-10-08

Family

ID=43298556

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177022797A Expired - Fee Related KR101905050B1 (ko) 2009-06-05 2010-06-04 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법
KR1020117031182A Ceased KR20120030112A (ko) 2009-06-05 2010-06-04 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117031182A Ceased KR20120030112A (ko) 2009-06-05 2010-06-04 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법

Country Status (15)

Country Link
US (2) US20120088807A1 (https=)
EP (1) EP2437749B8 (https=)
JP (2) JP5806210B2 (https=)
KR (2) KR101905050B1 (https=)
CN (2) CN102458416A (https=)
AU (1) AU2010256442B2 (https=)
CA (1) CA2764499A1 (https=)
DK (1) DK2437749T3 (https=)
ES (1) ES2661216T3 (https=)
IL (2) IL216443A (https=)
MX (1) MX344725B (https=)
PL (1) PL2437749T3 (https=)
SG (3) SG10201810806UA (https=)
WO (1) WO2010141842A2 (https=)
ZA (1) ZA201108909B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542155B1 (en) 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
CN103957923B (zh) * 2011-09-12 2018-05-25 卡维昂公司 用于抑制包括癌干细胞在内的干细胞的增殖、发育或分化的hs.459642单基因簇产物的拮抗剂
US11642353B2 (en) 2014-02-06 2023-05-09 The Procter & Gamble Company Hair care composition comprising antidandruff agent and polyquaternium-6
US11058624B2 (en) 2014-02-06 2021-07-13 The Procter And Gamble Company Hair care composition comprising cationic polymers and anionic particulates
DK3364993T3 (da) 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
CN110770221B (zh) 2017-04-26 2023-09-08 卡维昂公司 用于改善记忆和认知以及用于治疗记忆和认知障碍的方法
TWI879741B (zh) 2018-10-03 2025-04-11 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
MX2021003585A (es) 2018-10-04 2021-05-28 Procter & Gamble Composicion para el cuidado personal que comprende compuesto organico solido insoluble en agua.
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
US20060000320A1 (en) * 2004-06-30 2006-01-05 Hutton William M Ratchet wrench tool assembly for underground work and process of using
US9212127B2 (en) * 2004-08-20 2015-12-15 University Of Virginia Patent Foundation T type calcium channel inhibitors
AU2005277154B2 (en) * 2004-08-20 2011-11-24 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
CN100546579C (zh) * 2006-12-30 2009-10-07 南京工业大学 替莫唑胺聚乳酸纳米微球与制剂及其制备方法
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium

Also Published As

Publication number Publication date
MX2011012940A (es) 2012-04-20
JP6159958B2 (ja) 2017-07-12
KR20170097237A (ko) 2017-08-25
EP2437749B8 (en) 2018-02-21
EP2437749A4 (en) 2013-04-17
AU2010256442B2 (en) 2016-07-21
SG10201402863PA (en) 2014-10-30
PL2437749T3 (pl) 2018-04-30
WO2010141842A2 (en) 2010-12-09
MX344725B (es) 2017-01-05
SG10201810806UA (en) 2019-01-30
IL216443A (en) 2016-11-30
CN106177963A (zh) 2016-12-07
IL248482B (en) 2020-08-31
WO2010141842A3 (en) 2011-04-21
US20180228822A1 (en) 2018-08-16
JP2012528890A (ja) 2012-11-15
ES2661216T3 (es) 2018-03-28
ZA201108909B (en) 2013-02-27
IL248482A0 (en) 2016-12-29
CA2764499A1 (en) 2010-12-09
EP2437749A2 (en) 2012-04-11
US20120088807A1 (en) 2012-04-12
KR20120030112A (ko) 2012-03-27
SG176678A1 (en) 2012-01-30
CN102458416A (zh) 2012-05-16
EP2437749B1 (en) 2017-12-20
JP5806210B2 (ja) 2015-11-10
IL216443A0 (en) 2012-02-29
DK2437749T3 (da) 2018-01-29
AU2010256442A1 (en) 2012-01-19
JP2016028058A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
KR101905050B1 (ko) 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법
Guise Antitumor effects of bisphosphonates: promising preclinical evidence
KR102438597B1 (ko) 항종양제의 투여 방법
JP2018087228A (ja) がんのためのグルフォスファミド組み合わせ療法
JP2015505313A (ja) 癌を治療するための併用療法
Wu et al. A novel peptide to treat oral mucositis blocks endothelial and epithelial cell apoptosis
JP2002534378A (ja) ヒスタミンによって誘導される相乗的殺腫瘍応答
CA2736322C (en) 3,3', 4,4'-tetrahydroxy-2,2' -bipyridine-n,n' -dioxides for the treatment of renal cell carcinoma
US10751352B2 (en) Pharmaceutical composition for preventing or treating cancer
WO2016166761A1 (en) Combination therapies and uses thereof in the treatment of cancer
CN117083086A (zh) 腺苷二磷酸核糖在放射和／或抗癌治疗辅助疗法中的应用
JP7514563B2 (ja) オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物
JP6197065B2 (ja) 腎細胞癌の改良された治療
HK1168764B (en) Interlaced method for treating cancer or a precancerous condition
HK1168764A (en) Interlaced method for treating cancer or a precancerous condition
KR20210058586A (ko) 실데나필 및 rock 저해제를 포함하는 뇌졸중 치료용 약학적 조성물
DE102008031036A1 (de) Dasatinib zur Anwendung in der Organtransplantation
TW201513871A (zh) 用於癌症治療之抗群集素（ｃｌｕｓｔｅｒｉｎ）單一療法
WO2018069924A1 (en) Non-cytotoxic combination therapies and uses thereof in the treatment of cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

Not in force date: 20210929

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210929

St.27 status event code: N-4-6-H10-H13-oth-PC1903